{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:04:16Z","timestamp":1780113856146,"version":"3.54.0"},"reference-count":20,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2026,5,30]]},"DOI":"10.1536\/ihj.26-033","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:10:43Z","timestamp":1778883043000},"page":"275-279","source":"Crossref","is-referenced-by-count":0,"title":["Percutaneous Coronary Intervention for Coronary Events during Tyrosine Kinase Inhibitor Therapy in Leukemia Patients"],"prefix":"10.1536","volume":"67","author":[{"given":"Asaki","family":"Saijo","sequence":"first","affiliation":[{"name":"Department of Cardiology, Toranomon Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Toranomon Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Konishi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Toranomon Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Maze","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Toranomon Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinatsu","family":"Komiyama","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Toranomon Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Harima","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Toranomon Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yo","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Toranomon Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahide","family":"Kodama","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Toranomon Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Hochhaus A, Baccarani M, Silver RT, <i>et al<\/i>. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020; 34: 966-84.","DOI":"10.1038\/s41375-020-0776-2"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Luskin MR. Ph+ ALL: new approaches for upfront therapy. Hematology Am Soc Hematol Educ Program 2024; 2024: 78-85.","DOI":"10.1182\/hematology.2024000532"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol 2015; 33: 4210-8.","DOI":"10.1200\/JCO.2015.62.4718"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Li W, Croce K, Steensma DP, <i>et al<\/i>. Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors. J Am Coll Cardiol 2015; 66: 1160-78.","DOI":"10.1016\/j.jacc.2015.07.025"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Herrmann J, Yang EH, Iliescu CA, <i>et al<\/i>. Vascular toxicities of cancer therapies: the old and the new-an evolving avenue. Circulation 2016; 133: 1272-89.","DOI":"10.1161\/CIRCULATIONAHA.115.018347"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Pasvolsky O, Leader A, Iakobishvili Z, <i>et al<\/i>. Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia. Cardiooncology 2015; 1: 5.","DOI":"10.1186\/s40959-015-0008-5"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Shindo M, Komiyama C, Yamaguchi T, <i>et al<\/i>. Ponatinib-Related Vasospastic Angina. Int Heart J 2024; 65: 349-53.","DOI":"10.1536\/ihj.23-355"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Cortes JE, Kim DW, Pinilla-Ibarz J, <i>et al<\/i>. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013; 369: 1783-96.","DOI":"10.1056\/NEJMoa1306494"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Moslehi JJ. Cardiovascular Toxic Effects of Targeted Cancer Therapies. N Engl J Med 2016; 375: 1457-67.","DOI":"10.1056\/NEJMra1100265"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Aichberger KJ, Herndlhofer S, Schernthaner GH, <i>et al<\/i>. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011; 86: 533-9.","DOI":"10.1002\/ajh.22037"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Breccia M, Muscaritoli M, Gentilini F, <i>et al<\/i>. Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. Leuk Res 2007; 31: 1770-2.","DOI":"10.1016\/j.leukres.2007.01.024"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Zhang Y, Diamond SL. Src family kinases inhibition by dasatinib blocks initial and subsequent platelet deposition on collagen under flow, but lacks efficacy with thrombin generation. Thromb Res 2020; 192: 141-51.","DOI":"10.1016\/j.thromres.2020.05.012"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Gover-Proaktor A, Leshem-Lev D, Winograd-Katz S, <i>et al<\/i>. Dasatinib induces endothelial dysfunction leading to impaired recovery from ischaemia. Br J Haematol 2024; 205: 1011-6.","DOI":"10.1111\/bjh.19595"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, <i>et al<\/i>. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022; 43: 4229-361.","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 2021; 42: 2439-54.","DOI":"10.1093\/eurheartj\/ehab309"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Harada A, Ueshima H, Kinoshita Y, <i>et al<\/i>. Absolute risk score for stroke, myocardial infarction, and all cardiovascular disease: Japan Arteriosclerosis Longitudinal Study. Hypertens Res 2019; 42: 567-79.","DOI":"10.1038\/s41440-019-0220-z"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Li Y, Yatsuya H, Tanaka S, <i>et al<\/i>. Estimation of 10-Year Risk of Death from Coronary Heart Disease, Stroke, and Cardiovascular Disease in a Pooled Analysis of Japanese Cohorts: EPOCH-JAPAN. J Atheroscler Thromb 2021; 28: 816-25.","DOI":"10.5551\/jat.58958"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Caocci G, Mulas O, Abruzzese E, <i>et al<\/i>. Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. Hematol Oncol 2019; 37: 296-302.","DOI":"10.1002\/hon.2606"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Molica M, Scalzulli E, Colafigli G, <i>et al<\/i>. Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia. Ther Adv Hematol 2019; 10: 2040620719826444.","DOI":"10.1177\/2040620719826444"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Pushpam D, Bakhshi S. Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician&apos;s perspective. Daru 2020; 28: 371-85.","DOI":"10.1007\/s40199-019-00321-z"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/67\/3\/67_26-033\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T03:30:58Z","timestamp":1780111858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/67\/3\/67_26-033\/_article"}},"subtitle":["A Case Series"],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.26-033","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"article-number":"26-033"}}